Non-alcoholic fatty liver disease is on the rise and mainly stems from metabolic dysfunction. Dr Sood shares five facts about ...
Kerala researchers study 386 products, covering Ayurveda, Homoeopathy, Siddha, Unani, other traditional remedies. Findings ...
Is your liver health in danger? Scroll down to know what liver damage feels and looks like and what signs the body sends when ...
Fatty liver disease is becoming increasingly common, yet many people still underestimate how serious it can be. Because the ...
LFT slightly high. There is no pain. No yellowing of the eyes. No weakness. So it is easy to brush it aside. But the liver rarely shouts in the beginning. It whispers.Liver Function Tests, or LFTs, ...
Fatty liver disease sounds mild, almost harmless. That name alone pushes many people into denial. There is usually no pain, ...
This study investigates the association between liver fibrosis and diabetic peripheral neuropathy (DPN) in patients with type ...
Now looking beyond NASH, PEMB has the potential to address major unmet medical needs in both AUD and ALD because of a similar ...
The Phase III trial is powered on the 1.8 mg dose, with the higher 2.4 mg arm viewed as an opportunity for additional upside rather than a necessity. If the 2.4 mg dose fails to deliver clear ...
(Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, ...
Altimmune, Inc. (NASDAQ:ALT) Q4 2025 Earnings Call Transcript March 5, 2026 Altimmune, Inc. misses on earnings expectations. Reported EPS is $-0.27191 EPS, expectations were $-0.25. Operator: Good ...
The Company will issue a release after the oral presentation that will include the 5-year OS data, which is the longest OS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results